Current Queue

The Illumina HiSeq 2500 Sequencer has two run modes: the High Output (HO) mode and the Rapid Run (RR) mode. The HO Mode is more cost-effective, yet it takes longer to run and our users need to wait until all 8 lanes of a HO flow cell are filled up. To help our users plan their runs, we provide the following track form for lane use.

Filled lanes represent completed libraries that are ready for sequencing and tentative lanes represent samples currently in preparation. The client's corresponding quote number is also included in the queue. 

If you need faster service, please contact us for a Rapid Run or a MiSeq run. An RR flow cell has only two lanes to fill and can sequence up to 250 nucleotides (instead of 100 nucleotides of a HO run).

 

Sequencing Queue for HiSeq 2500 High Output/Rapid Run Modes and MiSeq

(Updated on 03/21/2017)​​

 


 

Currently Running on HiSeq: RR-PE150 (Q#268-RU), RR-SR100 (Q#269-JB)

Next in Queue for HiSeq HO/RR Mode: HO-SR100

Queue for HiSeq HO/RR Mode: 

 


 

Currently Running on MiSeq: MSv3-PE300 (BS-Q#266)

Next in Queue for MiSeq: 

Queue for MiSeq: 

 


 

Lanes on Next HO Flow Cells 

Run Format* 1 2 3 4 5 6 7 8

SR-50

Empty Empty Empty Empty Empty​ Empty​ Empty​ Empty​
SR-100

Filled (Q#270-SM)

Filled (Q#270-SM)

Filled (Q#270-SM)

Filled (Q#270-SM)

Filled (Q#270-SM)

Filled (Q#270-SM)

Filled (Q#267-LX)

Filled (Q#267-LX)

PE-50

Empty Empty Empty Empty Empty Empty Empty Empty
PE-100

Empty

Empty

Empty

Empty

Empty

Empty

Empty

Empty

  SR50: Single Read 50 bp 

  SR100: Single Read 100 bp 

  PE50: Paired End 50 bp

​  PE100: Paired End 100 bp.

 


CMADP Events

Special seminar by Dr. Kevin W. Plaxco
Professor of Chemistry & Biochemistry
UC Santa Barbara

Wednesday, April 19, 2017 at 4:00pm
School of Pharmacy, Room 3020

"Counting molecules, dodging blood cells: real-time molecular measurements directly in the living body"
The development of technology capable of continuously tracking the levels of drugs, metabolites, and biomarkers in situ in the body would revolutionize our understanding of health and our ability to detect and treat disease. It would, for example, provide clinicians with a real-time window into organ function and would enable therapies guided by patient-specific, real-time pharmacokinetics, opening a new dimension in personalized medicine. In response my group has pioneered the development of a “biology-inspired” electrochemical approach to monitoring specific molecules that supports real-time measurements of arbitrary molecular targets (irrespective of their chemical reactivity) directly in awake, fully ambulatory subjects.
KU Today